Wells Fargo lowers Health Catalyst price target to $1.5
Wells Fargo analyst Stan Berenshteyn maintains an Equal-Weight rating on Health Catalyst (NASDAQ: HCAT). The price target was lowered from $1.75 to $1.5, reflecting a modest downward revision in valuation expectations.
*this image is generated using AI for illustrative purposes only.
Wells Fargo analyst Stan Berenshteyn maintains an Equal-Weight rating on Health Catalyst (NASDAQ: HCAT) while lowering the price target from $1.75 to $1.5.
The adjustment reflects a revised valuation outlook for the healthcare technology company, though the neutral stance indicates no immediate recommendation for over- or under-weighting in portfolios.
Analyst Action
Wells Fargo reduced the price target by $0.25, citing updated market conditions or internal modeling adjustments specific to Health Catalyst’s trajectory. The Equal-Weight rating remains unchanged, suggesting the stock is fairly valued relative to its peers at current levels.
| Metric | Previous | Current |
|---|---|---|
| Price Target | $1.75 | $1.5 |
| Rating | Equal-Weight | Equal-Weight |
What specific changes in Health Catalyst's internal modeling or market conditions prompted Wells Fargo to lower the price target while maintaining an Equal-Weight rating?
How does the new $1.50 price target compare to current consensus estimates from other major Wall Street analysts covering HCAT?
Could this valuation adjustment signal broader headwinds for healthcare technology firms, or is it isolated to Health Catalyst's specific growth trajectory?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
